Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MNOV – Medicinova Inc

MediciNova, Inc.
MNOV
$1.36
Name : MediciNova, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $66,702,832.00
EPSttm : -0.23
finviz dynamic chart for MNOV
MediciNova, Inc.
$1.36
6.85%
$0.1

Float Short %

0.41

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

-0.06

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

1.46

Target Price

7.5

Analyst Recom

1

Performance Q

-20.65

Relative Volume

0.28

Beta

0.44

Ticker: MNOV




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-04-14MNOV1.440.120.00564
2025-04-15MNOV1.410.110.00574
2025-04-16MNOV1.440.110.00574
2025-04-17MNOV1.450.11999.99584
2025-04-18MNOV1.450.11999.99584
2025-04-21MNOV1.470.11999.99584
2025-04-22MNOV1.480.26999.9939
2025-04-23MNOV1.490.290.0040
2025-04-24MNOV1.510.220.0050
2025-04-25MNOV1.560.12328767123288082
2025-04-28MNOV1.55990.12328767123288082
2025-04-29MNOV1.540.120.0082
2025-04-30MNOV1.57990.120.0082
2025-05-01MNOV1.510.120.0082
2025-05-02MNOV1.520.120.0082
2025-05-05MNOV1.5N/AN/A0
2025-05-06MNOV1.52N/AN/A0
2025-05-07MNOV1.54N/AN/A0
2025-05-08MNOV1.49N/AN/A0
2025-05-09MNOV1.480.070.00140
2025-05-12MNOV1.440.070.00140
2025-05-13MNOV1.45580.060.00150
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-04-14MNOV1.40- - -0.50
2025-04-15MNOV1.40- - -0.50
2025-04-16MNOV1.42- - -0.50
2025-04-17MNOV1.45- - -0.50
2025-04-18MNOV1.45- - -0.50
2025-04-21MNOV1.47- - -0.50
2025-04-22MNOV1.50- - -0.50
2025-04-23MNOV1.49- - -0.50
2025-04-24MNOV1.52- - -0.50
2025-04-25MNOV1.56- - -0.50
2025-04-28MNOV1.56- - -0.50
2025-04-29MNOV1.59- - -0.50
2025-04-30MNOV1.52- - -0.50
2025-05-01MNOV1.47- - -0.50
2025-05-02MNOV1.51- - -0.50
2025-05-05MNOV1.50- - -0.50
2025-05-06MNOV1.49- - -0.50
2025-05-07MNOV1.49- - -0.50
2025-05-08MNOV1.49- - -0.50
2025-05-09MNOV1.47- - -0.50
2025-05-12MNOV1.44- - -0.50
2025-05-13MNOV1.46- - -0.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-04-14MNOV0.006.110.50
2025-04-15MNOV0.006.110.50
2025-04-16MNOV0.006.110.50
2025-04-17MNOV0.006.110.50
2025-04-18MNOV0.006.110.50
2025-04-21MNOV0.006.210.50
2025-04-22MNOV0.006.210.50
2025-04-23MNOV0.006.210.50
2025-04-24MNOV0.006.210.50
2025-04-25MNOV0.006.210.50
2025-04-28MNOV0.006.170.41
2025-04-29MNOV0.006.170.41
2025-04-30MNOV0.006.170.41
2025-05-01MNOV0.006.170.41
2025-05-02MNOV0.006.170.41
2025-05-05MNOV0.006.080.41
2025-05-06MNOV0.006.080.41
2025-05-07MNOV0.006.080.41
2025-05-08MNOV0.006.080.41
2025-05-09MNOV0.006.080.41
2025-05-12MNOV0.003.560.41
2025-05-13MNOV0.003.560.41
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.06

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

3.56

Beta

0.44

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

12

Growth Score

21

Sentiment Score

14

Actual DrawDown %

89

Max Drawdown 5-Year %

-89.7

Target Price

7.5

P/E

Forward P/E

PEG

P/S

P/B

1.36

P/Free Cash Flow

EPS

-0.23

Average EPS Est. Cur. Y​

-0.5

EPS Next Y. (Est.)

-0.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.28

Return on Equity vs Sector %

-44.7

Return on Equity vs Industry %

-27.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

MediciNova, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading